Harbour BioMed and Evinova China have formed a collaboration to implement AI and digital technologies to improve biologics development.
The partnership intends to enhance the efficiency of AI-enabled drug development and create an open ecosystem for research and development (R&D).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies will build on their respective strengths and expertise to accelerate progress in AI-driven biologics research.
Harbour BioMed founder, chairman and CEO Dr Jingsong Wang stated: “We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development. Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice technology platform.
“Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world.”
Evinova China general manager Nate Zhang stated: “Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our AI-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcomes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“To realise our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harbouring global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world.”
Harbour BioMed’s antibody technology platform, Harbour Mice, is central to the company’s product pipeline, generating fully human monoclonal antibodies in both heavy chain-only and conventional two heavy and two light chain formats.
The company integrates these technologies with single B-cell cloning for next-generation antibody discovery and development targeting inflammatory, oncology and immunology diseases.
Evinova is a distinct digital health business within AstraZeneca Group and operates globally as a health-tech business.
In June 2025, Harbour BioMed entered a partnership with Otsuka Pharmaceutical focusing on the development of HBM7020, a B-cell maturation antigen (BCMA) xcluster [cross cluster] of differentiation 3 (CD3) bispecific T-cell engager aimed at treating autoimmune diseases.
